医学
化学免疫疗法
正电子发射断层摄影术
淋巴瘤
核医学
PET-CT
霍奇金淋巴瘤
滤泡性淋巴瘤
放射治疗
标准摄取值
放射科
医学物理学
内科学
美罗华
作者
Akram Al‐Ibraheem,Felix M. Mottaghy,Malik E. Juweid
标识
DOI:10.1053/j.semnuclmed.2022.10.006
摘要
18F-FDG-PET/CT is now an integral part of the workup and management of patients with Hodgkin's lymphoma (HL). PET/CT is currently routinely performed for staging and for response assessment at the end of treatment. Interim PET/CT is typically performed after 1-4 of 6-8 chemo/chemoimmunotherapy cycles ± radiation for prognostication and potential treatment escalation or de-escalation early in the course of therapy, a concept known as response-or risk-adapted treatment. Quantitative PET is an area of growing interest. Metrics such as the standardized uptake value (SUV), metabolic tumor volume, total lesion glycolysis, and their changes with treatment are being investigated as more reproducible and, potentially, more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value. This review highlights the most relevant applications of PET/CT in HL, its strengths and limitations, as well as recent efforts to implement PET/CT-based metrics as promising tools for precision medicine. Finally, the value of PET/CT for response assessment to immunotherapy is discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI